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Background: Recently anti-CCP testing has become popular in the diagnosis of rheumatoid arthritis (RA). However,
the inadequate reporting of the relevant diagnostic studies may overestimate and bias the results, directing
scientists into making false decisions. The aim of the present study was to evaluate the reporting quality of studies
used anti-CCP2 for the diagnosis of RA and to explore the impact of reporting quality on pooled estimates of
diagnostic measures.
Methods: PubMed was searched for clinical studies investigated the diagnostic accuracy of anti-CCP. The studies
were evaluated for their reporting quality according to STARD statement. The overall reporting quality and the
differences between high and low quality studies were explored. The effect of reporting quality on pooled
estimates of diagnostic accuracy was also examined.
Results: The overall reporting quality was relatively good but there are some essential methodological aspects of
the studies that are seldom reported making the assessment of study validity difficult. Comparing the quality of
reporting in high versus low quality articles, significant differences were seen in a relatively large number of
methodological items. Overall, the STARD score (high/low) has no effect on the pooled sensitivities and specificities.
However, the reporting of specific STARD items (e.g. reporting sufficiently the methods used in calculating the
measures of diagnostic accuracy and reporting of demographic and clinical characteristics/features of the study
population) has an effect on sensitivity and specificity.
Conclusions: The reporting quality of the diagnostic studies needs further improvement since the study quality
may bias the estimates of diagnostic accuracy.
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Meta-analysisBackground
Rheumatoid arthritis (RA) is a chronic, systemic inflam-
matory disorder that affects many tissues and organs,
mainly synovial joints [1]. The disease leads progressively
to the destruction of articular cartilage and ankylosis of
the joints [2]. Although the cause of RA is unknown,* Correspondence: zintza@med.uth.gr
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reproduction in any medium, provided the orautoimmunity plays a pivotal role in both its chronicity
and progression [3]. RA affects females more frequently
than males and it is diagnosed mainly in age 40–60 years
[4].
The diagnosis of RA is based on clinical criteria and
laboratory tests. Regarding the later tests, the presence
of the rheumatoid factor (RF), an autoantibody, consists
one of the American College of Rheumatology (ACR)
criteria for presence and severity of RA [5]. However,
RF has a limited specificity since it can be detected
in other autoimmune or infectious diseases, and inal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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antibodies (anti-CCP) are other autoantibodies that
may be detected in RA patients. Recently anti-CCP
testing has become substantial part of ACR-EULAR
classification criteria for RA [6]. There is evidence that
CCP-assays provide comparable performance with that
of RF [7]. However, analysis of the association between
anti-CCP antibody titre and RA activity produced
contradictory results [8,9]. Anti-CCP2 assay is the most
popular because of its high diagnostic specificity and its
predictive and prognostic value in RA [10-12].
Currently, diagnostic studies on anti-CCP assays are
publishing with a high rate [13]. However, overestimated
and biased results from poorly designed and reported
studies may direct scientists into making false decisions
[14-16]. The reporting information on design and con-
duct of diagnostic studies is crucial, though, its absence
has already been noticed [17,18]. Nevertheless, appropri-
ate reporting may allow researchers to detect potential
bias in studies’ internal validity, to assess generalizability
and applicability of their results [19]. A survey of pub-
lished studies of diagnostic accuracy showed that the
methodological quality was not optimal. In addition, in-
formation on issues like study design, conduct and data
analysis was often not reported [20,21].
Inadequate reporting of the published diagnostic accur-
acy studies may restrict the generalizability, applicability
and credibility of studies’ results. A number of guidelines
and statements have been developed to improve the qual-
ity of a variety of study designs [22], including the diagnos-
tic accuracy studies [19]. In particular, in order to improve
the reporting of diagnostic accuracy studies, the Standards
for Reporting of Diagnostic Accuracy (STARD) statement
has been proposed (http://www.stard-statement.org/) [19].
The STARD statement is a checklist of 25 criteria that
diagnostic accuracy studies should conform to in order to
make their conclusions easier to assess, interpret and
generalize, and lead as a result to better decisions in diag-
nosis. However, STARD does not assess the actual quality
of the research study but the reporting quality, two issues
which are not necessarily correlated. In addition to STARD,
another tooled has been proposed, called QUADAS, for
assessing the methodological quality of diagnostic accuracy
studies [23]. Recently, QUADAS was used to evaluate the
quality of anti-CCP RA studies in a meta-analysis [13].
The aim of the present study was twofold: first, to
evaluate the reporting quality of studies used anti-CCP2
for the diagnosis of RA, according to the STARD state-
ment, and second, to investigate whether quality of
reporting is associated with the effect size of diagnostic
metrics using meta-analytic techniques (data synthesis).
The analysis was focused on the reporting of methods
and results sections of the STARD statement. The effect
of quality on diagnostic accuracy was focused on studiesscored as “high quality” and “low quality”, and for spe-
cific items of STARD.
Methods
Study identification
PubMed was searched for clinical studies, published
from January 1987 (date of imposing the revised ACR
criteria [5] to September 2010 that assessed the utility of
anti-CCP2 assay in the diagnosis of RA. The search used
the following strategy: (("diagnosis" or "diagnostic" or
"sensitivity" or "specificity") and ("rheumatoid arthritis"
or "RA") and ("anti-cyclic citrullinated peptide anti-
bodies" or "anti-CCP" or "antiCCP" or "anti-CCP2" or
"antiCCP2")).
The authors independently reviewed the abstracts to
determine the eligibility of each article to potentially
meet the search strategy. The references of the retrieved
articles were also searched. Only articles in English lan-
guage, published as full papers or short reports were
considered in our study. Reviews, editorials, letters and
comments were excluded. The agreement level was
reported using Kappa statistics.
Study selection
We included studies that evaluated the utility of anti-CCP2
antibody for diagnosis of RA with more than 10 partici-
pants enrolled that provided data sufficient to estimate
both sensitivity and specificity. As controls were defined
participants free of RA (i.e. diseased with other conditions
or healthy). Disagreements were resolved by discussing the
full articles.
Data abstraction
The data were abstracted from each study by two
authors (AP and DZ) independently. Data were extracted
by using a standardized form that included study setting
and technical details of the assay, demographic character-
istics of the patients and 2×2 contingency tables (disease
status and test outcome) needed to calculate at least the
sensitivity and specificity.
When articles reported more than one set of 2×2 data
(such as assays data from different manufacturers and/or
different cut-offs), then each data set was considered as
a different study. Also, articles reported data separately
for multiple control groups (diseased, healthy) were con-
sidered as separate studies. In overlapping studies, the
most recent and/or the largest study was recorded. The
agreement level was also reported using Kappa statistics.
Study quality assessment with STARD
Although all items in the STARD statement are considered
important to help to improve the quality of reporting diag-
nostic accuracy studies, some are more subjective than
others to assess potential biases. Thus, in the present study
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that correspond to methods and results sections (eleven
items in each category). Thus, in total, 22 items were con-
sidered (Table 1). In order to determine better if an item is
accurately reported in the articles, we took into account
the guidance provided by the STARD Explanation and
Elaboration document [21]. All items were investigated in
terms of whether they were reported, not whether they
were actually carried out during the study. Items were to
be scored as “yes” if they were reported in enough detail
to allow the reader to judge that the definition had been
met. Especially in case of item (14) providing participant’s
information about the patient recruitment, the item was
coded as “yes” only when the flow diagram was given or
explicitly described (i.e. the number of controls per case
was specified and the matching variables were clearly
stated). Alternatives responses (apart from “yes” or “no”)
and unclear responses to each item were coded as negative
responses.
Estimation of diagnostic accuracy
The estimation of the diagnostic accuracy was based on
the sensitivity (Se) and specificity (Sp). Se and Sp were
calculated from contingency tables abstracted from each
study.
Data synthesis and analysis
For each study the diagnostic metrics (Se, Sp, positive and
negative likelihood ratio) were calculated. A bivariate
model [24,25] was used to estimate summary sensitivity
and specificity, with 95% confidence and prediction regions
around the summary points. Hierarchical SROC analysis
that allows for between-study heterogeneity was also
applied to four or more studies [25]. Heterogeneity was
evaluated visually by using the SROC curve and numeric-
ally by using the variance of the logit-transformed sensitiv-
ity and specificity. A smaller value of variance indicates
low between study heterogeneity. The statistical analysis
was performed using Stata v.10 (metandi and metandiplot
commands [26]) (StataCorp, College Station, Texas) and
SPSS, version 13.0 (SPSS Inc., Chicago).
Effect of study quality
In addition, to the overall percentages of reporting the
STARD statement items, the quality of reporting in high
versus low quality articles was explored. Studies were clas-
sified as high quality of reporting when quality score≥ 9
and as lower quality when quality score < 9. The choice of
quality score = 9 as cut-off was the median of the overall
quality scores of studies. The overall quality score for each
article was calculated by summing the weighted score of
reported items. A unit weight was applied for each of the
item 2, 5, 7, 10, 13, 16 and 19 (considered subjectively
more “important”), whereas, a weight of 0.5 for each of theother items. The effect of study quality on diagnostic
accuracy was evaluated based on the level of quality (high/
low) and on the reporting results of the above “important”
STARD items. Then, the estimates of pooled sensitivities
and specificities were compared with a z-score test.
Results
Eligible studies
The literature review identified 364 articles that met the
search criteria in PubMed. Thereafter, these articles were
retrieved and screened for eligibility. Overall, a total of
103 unique articles remained for analysis having
complete full-text evaluation. Figure 1 presents a flow
diagram of retrieved articles and articles excluded with
specification of reasons. The agreement in article evaluation
for eligibility and in extracting the data was both relatively
high (kappa=0.74 (0.70-0.78) and kappa=0.86 (0.82-0.90)),
respectively. A full list of the 103 articles that were retrieved
as full-text and included in final analysis is located at the
Web site http://biomath.med.uth.gr.
Study characteristics
The characteristics of studies included in the analysis are
shown in Additional file 1: Table S1. A list of journals
that endorsed the STARD statement is shown in
Additional file 2: Table S2. The 103 eligible articles were
published during the period 2003–2010. Consequently,
all the eligible articles were published after the introduc-
tion of the STARD statement (i.e. 2003). In total 35
different populations (countries) were referred in the
eligible articles. Most of the articles conducted in Europe
(51 articles, 49.5%) and thereafter in Asia (31 articles,
30.1%), in Africa (7 articles, 6.8%), in North America
(7 articles, 6.8%), in South America (6 articles, 5.8%) and
in Oceania (1 article, 1.0%). Most of the articles referred to
studies conducted in teaching hospitals (52 articles, 50.5%)
and the second most frequent studies’ setting was the
rheumatologic clinics (31 articles, 30.1%). In 13 out of 103
articles, the detection of anti-CCP2 antibody was done
with more than one assay. The four most popular
manufacturer assays used, were the Euro-Diagnostica
(33 studies, 25.0%), the Axis-Shield (32 studies,
24.2%), the Inova Diagnostics (25 studies, 18.9%) and
the Euroimmun (19 studies, 14.4%). A variety of cut-
offs were used to define a positive test result accord-
ing to different manufacturers, but in 9 articles/studies
the threshold used was not explicitly given. Control group
consisted of participants free of RA (i.e. diseased with other
conditions or healthy). From all the above reasons, the 103
articles we had, concluded to a total of 132 studies for the
meta-analysis. The mean age of RA participants in the
studies, where reported, ranged from 30 years to 70 years
(missing information in 37 articles, 35.9%) and the propor-
tion of women RA participants, where reported, ranged
Table 1 Proportion of reporting of the items in the STARD statement, overall and in a total of 103 diagnostic studies
involving rheumatoid arthritis by STARD score group
STARD* items Overall % of
reporting item
n=103
% of reporting item P-value{
Lower quality
articles (score < 9)
n = 50
Higher quality
articles (score≥ 9)
n = 53
METHODS
1. The study population: The inclusion and exclusion criteria,
setting and locations where the data were collected.
88.3 78.0 98.1 0.002
2. Participant recruitment: Was recruitment based on presenting
symptoms, results from previous tests, or the fact that the
participants had received the index tests or the reference standard?
98.1 98.0 98.1 0.999
3. Participant sampling: Was the study population a consecutive
series of participants defined by the selection criteria in item 3
and 4? If not, specify how participants were further selected.
89.3 88.0 90.6 0.756
4. Data collection: Was data collection planned before the index
test and reference standard were performed (prospective study)
or after (retrospective study)?
95.1 90.0 100.0 0.024
5. The reference standard and its rationale. 74.8 52.0 96.2 <0.01
6. Technical specifications of material and methods involved
including how and when measurements were taken, and/or cite
references for index tests and reference standard.
57.3 48.0 66.0 0.075
7. Definition of and rationale for the units, cut-offs and/or
categories of the results of the index tests and the reference
standard.
77.7 68.0 86.8 0.032
8. The number, training and expertise of the persons executing and
reading the index tests and the reference standard.
20.4 8.0 32.1 0.003
9. Whether or not the readers of the index tests and reference
standard were blind (masked) to the results of the other test and
describe any other clinical information available to the readers.
18.4 12.0 24.5 0.130
10. Methods for calculating or comparing measures of
diagnostic accuracy, and the statistical methods used
to quantify uncertainty (e.g. 95% confidence intervals).
90.3 82.0 98.1 0.007
11. Methods for calculating test reproducibility, if done. # 88.0 100.0 86.4 0.999
RESULTS
12. When study was done, including beginning and ending dates
of recruitment.
41.7 26.0 56.6 0.003
13. Clinical and demographic characteristics of the study
population (e.g. age, sex, spectrum of presenting symptoms,
comorbidity, current treatments, recruitment centers).
87.4 78.0 96.2 0.007
14. The number of participants satisfying the criteria for inclusion
that did or did not undergo the index tests and/or the reference
standard; describe why participants failed to receive either test
(a flow diagram is strongly recommended).
12.6 2.0 22.6 0.002
15. Time interval from the index tests to the reference
standard, and any treatment administered between.
27.2 12.0 41.5 0.001
16. Distribution of severity of disease (define criteria) in those with
the target condition; other diagnoses in participants without the
target condition.
53.4 46.0 60.4 0.169
17. A cross tabulation of the results of the index tests
(including indeterminate and missing results) by the
results of the reference standard; for continuous
results, the distribution of the test results by the
results of the reference standard.
94.2 92.0 96.2 0.428
18. Any adverse events from performing the index tests or the
reference standard.
11.7 10.0 13.2 0.761
19. Estimates of diagnostic accuracy and measures of
statistical uncertainty (e.g. 95% confidence intervals).
74.8 54.0 94.3 <0.01
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Table 1 Proportion of reporting of the items in the STARD statement, overall and in a total of 103 diagnostic studies
involving rheumatoid arthritis by STARD score group (Continued)
20. How indeterminate results, missing responses and
outliers of the index tests were handled.
7.8 6.0 9.4 0.716
21. Estimates of variability of diagnostic accuracy
between subgroups of participants, readers or
centers, if done. #
100.0 100.0 100.0 -
22. Estimates of test reproducibility, typically
imprecision (as CV) at 2 or 3 concentrations, if done. #
96.0 100.0 95.5 0.999
(Lower quality articles, score < 9 and higher quality articles, score ≥ 9).
# for smaller number of articles (n = 25 articles for items 11 & 22), (n = 23 articles for item 21).
{ P values were obtained from Fisher’s exact test in order to express the association between proportions for reporting an item across the two groups of articles.
* STARD = Standards for Reporting of Diagnostic Accuracy.
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28.2%). Fifty three articles (51.5%) were published in high
quality articles (STARD score≥9) and 50 articles (48.5%) in
lower quality articles (STARD score <9) (Table 2).
Main results
Table 1 shows the overall proportion of reporting of the
22 items in the methods and results sections of the
STARD statement and the corresponding proportions
for high and low quality articles.
Overall, 10 items (six and four items in methods and
results sections, respectively) were reported by 85% or more
of the studies (Table 1). In methods, the items include the
reporting of 1) study population (inclusion/exclusion
criteria, setting, location), 2) participants recruitment
(eg. based on symptoms, previous testing), 3) participant
sampling, 4) data collection (prospective or retrospective
study), 5) methods for calculating or comparing measures
of diagnostic accuracy and statistical methods used to
quantify uncertainty and 6) methods for calculating repro-
ducibility, if done. In results, the items include the reportingFigure 1 Flow diagram of citations through the retrieval and the screof 1) clinical and demographic characteristics of the study
population (age, sex, presenting symptoms, comorbidity,
current treatment), 2) the cross tabulation or the distribu-
tion of the test results by the results of the reference stand-
ard, 3) estimates of variability of diagnostic accuracy
between subgroups of participants, centers, if done and
4) estimates of test reproducibility, if done.
Furthermore, 13 items (including the ten items already
mentioned above) were reported by 70% or more of the
studies. The 3 additional items were the reporting of
1) reference standard and its rationale of, 2) definition of
and rationale for the units, cut-offs and/or categories of
tests results and 3) estimates of diagnostic accuracy and
measures of statistical uncertainty.
In contrast, some items were reported only by a small
fraction of articles. For example, 20% of articles provided
the number, training and expertise of persons executing
the tests, 18% reported the blinding status, 13% provided
information on recruitment, 12% reported adverse
events and finally, 8% provided details about handling of
missing responses and outliers.ening process.
Table 2 Results of Meta-analysis
Group Articles, n Studies, n Sensitivity (95% ci), % Specificity (95% ci), %
All data 103 132 70.8 (68.3-73.2) 95.8 (94.9-96.6)
Effect of STARD score
High quality score 53 73 70.9 (67.5-74.1) 95.7 (94.4-96.7)
Low quality score 50 59 70.7 (67.0-74.1) 96.0 (94.8-97.0)
Effect of STARD item 2
Yes 101 129 70.8 (68.3-73.2) 95.8 (94.9-96.6)
No¥ 2 3 NA NA
Effect of STARD item 5
Yes 77 99 71.8 (69.0-74.5) 95.6 (94.5-96.5)
No 26 33 67.7 (62.6-72.4) 96.3 (94.9-97.4)
Effect of STARD item 7
Yes 80 103 71.0 (68.2-73.7) 95.9 (94.9-96.7)
No 23 29 70.0 (64.7-74.9) 95.6 (93.2-97.2)
Effect of STARD item 10
Yes 93 121 70.2 (67.5-72.7)* 95.9 (95.0-96.7)
No 10 11 77.5 (71.7-82.3) 94.5 (91.7-96.4)
Effect of STARD item 13
Yes 90 116 71.5 (68.9-74.1)** 95.6 (94.6-96.4)*
No 13 16 65.7 (59.7-71.2) 97.2 (96.2-97.9)
Effect of STARD item 16
Yes 55 66 73.3 (69.8-76.6) 94.6 (93.2-95.8)*
No 48 66 68.3 (64.9-71.5) 96.8 (95.7-97.7)
Effect of STARD item 19
Yes 77 105 70.5 (67.8-73.1) 95.8 (94.8-96.5)
No 26 27 72.3 (66.1-77.8) 96.4 (93.8-97.9)
¥ = non-applicable, <4 studies; *P < 0.05, **P = 0.06.
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In comparing the quality of reporting in high quality
(quality score ≥ 9) versus lower quality (quality score < 9)
articles, significant differences were seen in 11 items
(P < 0.05) (6 items in methods: study population, data
collection, reference standard, definition of units/cut-offs,
number/training/expertise of persons executing the tests,
methods for calculating diagnostic measures and 5 in
results: dates of recruitment, clinical/demographic charac-
teristics, information on recruitment, time interval between
tests, estimates of diagnostic accuracy). In all these items
high quality articles showed better performance. An item-
by-item comparison is presented in Table 1.
Impact of study quality on diagnostic estimates
Table 2 shows the meta-analysis’ overall results (pooled
sensitivities and specificities), the results according to
STARD score (high/low quality) and the results for specific
STARD items (comparison of outcome “yes” vs. “no”).
Overall, the pooled sensitivity and specificity were
70.8% (95% ci, 68.3% to 73.2%) and 95.8% (95% ci, 94.9%to 96.6%), respectively. Studies with high quality score
produced similar results with studies with low quality
score [sensitivity: 70.9% (95% ci, 67.5% to 74.1%) vs.
70.7% (95% ci, 67.0% to 74.1%) and specificity: 95.7%
(94.4% to 96.7%) vs. 96.0% (94.8% to 97.0%)]. In HSROC
analysis, sensitivity and specificity in high vs. low quality
studies were found approximately equal; though, a
slightly reduced variance of logit-transformed sensitivity
and specificity was found in the low quality studies (0.39
and 0.93, respectively) (Figures 2a and 2b).
In comparing specific items (“yes” vs. “not”), the estimates
of pooled sensitivities were statistically significant for items
10 and 13 [p=0.03 and p=0.06 (marginal), respectively]. In
addition, the estimates of pooled specificities were statisti-
cally significant for items 13 and 16 (p=0.01 and p=0.01,
respectively).
Discussion
The present study investigated the quality of reporting
of studies using the anti-CCP2 assay in RA patients
according to the STARD statement. The differences
Figure 2 Hierarchical summary receiver-operating characteristic (HSROC) plots for a) high quality studies and b) low quality studies.
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effect of reporting quality on pooled estimates of diag-
nostic metrics was also examined. Our analysis focused
on the reporting of methodological items (items in
method and results’ sections). In total, the 103 articles
(corresponding to 132 studies) covered a publication
period of 23 years. Almost the articles used in our ana-
lysis were published after the introduction of STARD
statement (only 4 of them were published during 2003,
year of STARD appearance).
Although the overall reporting quality was relatively
good (13 items were reported by 70% or more of the
studies) there are some essential methodological aspects of
the studies (such as number/training/expertise of persons
executing the tests, readers’ blinding to results, information
on recruitment, adverse events from performing the tests,
handling of missing responses and outliers) that are seldom
reported making it difficult for the reader to assess
explicitly the validity of a study. Comparing the quality of
reporting in high versus low quality articles, significant
differences were seen in a relatively large number of meth-
odological items (11 items referred to: study population,
data collection, reference standard, definition of units/cut-
offs, number/training/expertise of persons executing and
reading the tests, methods for calculating diagnostic mea-
sures, dates of recruitment, clinical/demographic character-
istics, information on recruitment, time interval between
tests, estimates of diagnostic accuracy).
Overall, the STARD quality score (high/low) has no
effect on pooled sensitivity and pooled specificity. How-
ever, the meta-analysis showed an effect for specific
STARD items. Studies not reporting sufficiently the
methods used in calculating the measures of diagnosticaccuracy (item 1), may have overestimated the sensitivity.
In addition, the reporting of demographic and clinical
characteristics/features of the study population (items 13
and 16) has affected the effect size of specificity, i.e. they
have overestimated it, indicating also a spectrum bias [19].
However, the findings of the present synthesis (sensitivity
of anti-CCP2, 71% and specificity, 96%) are compatible with
those of earlier reviews (Nishimura et al. [27]: sensitivity,
67% and specificity, 95%, Whiting et al. [13]: sensitivity,
67%, specificity, 96%). An overestimation of our overall sen-
sitivity might be resulted because of the lack of stratification
by study design or disease duration in the analysis.
In a recent review, Whiting et al. [13] compared the
accuracy of ACPA with that of RF in diagnosing RA in
patients with early symptoms of the disease. They also
assessed their studies for methodological quality by
using a modification of the QUADAS criteria (items
related to reporting quality, were removed). However,
the impact of quality effect in diagnostic accuracy was
not evaluated further. Nevertheless, the primary aim of
the present study was to evaluate the effect of quality of
reporting (according to STARD) in diagnostic accuracy
rather than evaluating the effect of methodological quality
(according to QUADAS); though, both tools can be useful
for assessing the quality of diagnostic studies in a different
perspective [28].
Applications of the STARD statement guidelines for
assessing the quality of reporting in diagnostic accuracy
studies, have been conducted in various medical fields
such as in the field of diagnostic endoscopy [29], of
juvenile idiopathic arthritis in peripheral joints [30], of
diabetic retinopathy screening [31], of glucose monitor
studies [32], of optical coherence tomography in glaucoma
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dysplasia of the hip [34] and in the field of screening
ultrasonography for trauma [35].
A limitation of the present study is that the literature
search was restricted to PubMed. In addition, some
studies may have been missed since we included only
studies that provided data to estimate both sensitivity
and specificity. However, the number of articles used is
relatively large and an overview of reporting quality of
studies may be obtained and the reached conclusions are
unlikely to be affected by omitted studies. We would like
to stress that lack of reporting of a STARD item does
not necessarily implies that this item was not performed.
Thus, a badly performed but well reported study will
necessarily receive full credit. Finally, the published stud-
ies have had different design settings, and involved dif-
ferent stages of rheumatoid arthritis (study design,
disease duration) which may question the synthesis of
information, and therefore, the generalizability of results.
In conclusion, our attempt to assess the reporting
quality of diagnostic accuracy studies in RA highlights
the need for further improvement. Implementation of
the quality reporting statements (e.g. CONSORT) have
already improved the quality of reporting in other fields
of medical research [36]. Thus, guidelines on the report-
ing of diagnostic accuracy studies are expected to im-
prove the quality of reports of diagnostic studies as well.
Finally, the study quality has no effect on the pooled
estimates of diagnostic accuracy.Additional files
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